A secondary analysis of the INVESTED trial found that high-dose trivalent influenza vaccines didn't significantly lower mortality or hospitalizations for patients with high-risk cardiovascular disease compared to standard-dose quadrivalent vaccines.
The study focused on the antibody response to these vaccines and how it relates to clinical outcomes among patients who had recent heart issues.
Results showed that high-dose vaccines produced a stronger antibody response for various influenza strains, indicating a better immune response despite no clear impact on health outcomes.